Please assess the completion status of the following clinical trial:

Trial Title: Kilimanjaro IPTi Drug Options Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* All infants attending EPI clinics at the 12 study health facilities for first vaccinations. Infants who live within the catchment area of the study health facility and are less than 3 months of age at the time of DPT and Polio 1 vaccination will be eligible for inclusion in the study.~Exclusion Criteria:~* Infants having any of the following conditions will be excluded: (1) history of allergy to study drugs; (2) history of convulsions; (3) clinical features of severe malnutrition or chronic illness including infants with signs of AIDS \[HIV prevalence in women of reproductive age in the study area was 11.5% in 1999\]39 (4) plans to leave the study area before 12 months of age.(5) weighs \<4.5 kgs (6) caretaker declines to give consent.

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 24 Months
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): IPTi placebo
- Sulphadoxine-pyrimethamine (Type: EXPERIMENTAL): IPTi SP
- Mefloquine (Type: EXPERIMENTAL): None
- Chlorproguanil dapsone (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).